Axogen to Showcase Nerve Repair Innovation at JPM 2026
ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 — Axogen, Inc. (NASDAQ: AXGN), a recognized leader in peripheral nerve...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
ALACHUA, Fla. and TAMPA, Fla., Dec. 17, 2025 — Axogen, Inc. (NASDAQ: AXGN), a recognized leader in peripheral nerve...
COPENHAGEN, November 6, 2025 — GN Store Nord A/S (GN) reported a strong Q3 2025 performance, achieving 1% organic...
Dallas, Texas, October 30, 2025 — Lantern Pharma Inc. (NASDAQ: LTRN) announced it will present two cutting-edge AI-driven drug-development...
Basel, Switzerland – October 30, 2025 — Roche Holding AG (SIX: RO, ROG; OTCQX: RHHBY) has successfully completed its...
Emeryville, California, October 29, 2025 — Kyverna Therapeutics Inc. (Nasdaq: KYTX) announced positive interim Phase 2 data from the...
DULUTH, Ga., Oct. 7, 2025 — Bridge to Life Ltd. has received FDA 510(k) clearance for its multi-sourced Belzer...
